FOCL

EDAP is a single-product HIFU bet dressed in the numbers of a company running out of room. FY2025 revenue was essentially flat at $70.5M (+1.6%), yet the net loss widened 42% to -$29.2M and operating income fell to -$24.7M (-35% operating margin). The MD&A explains the flat top line: management is deliberately winding down the ESWL business (Sonolith i-move discontinued, final system sales in H2 2025) and de-emphasizing third-party distribution to concentrate on proprietary HIFU. There is a real kernel here — U.S. sales jumped to 40% of consolidated revenue from 28%, driven by Focal One system sales, and R&D rose 15.5% to $9.66M — but that pivot is being funded by shareholders' balance sheet, not by the business.

The balance sheet is the disqualifier. Stockholders' equity was cut in half to $19.4M (-54.3%) against $59.6M of liabilities (+27%), a 3.07x liabilities/equity ratio, on an accumulated deficit of -$129M. Long-term debt exploded 608% to $15.9M — the European Investment Bank facility — and the filing's own risk summary leads with 'if we are unable to obtain additional financing when needed' and 'we have incurred substantial debt... servicing our debt requires a significant amount of cash.' Meanwhile cash fell 34% to $20.5M while operating cash flow was -$16.4M. That is roughly one year of runway at the current burn before debt service, which all but guarantees a capital raise — and the EIB warrants are explicitly flagged as a dilution/price-depression risk for the 37.5M share base.